Virus-mediated gene therapy is a promising strategy for numerous tissue engineering applications. Fibrin-based scaffolds have been previously used as vehicles for localised delivery of adenovirus to wound sites. However, their utility in the delivery of adeno-associated viruses to wound repair cells has not yet been determined. The influence of fibrin concentration on efficacy of delivery of AAV-2 to wound tissue was assessed in this study. Fibrin scaffolds containing recombinant AAV-2 encoding for β-galactosidase were polymerised in porous polyurethane discs and implanted subcutaneously in rats. A fibrin scaffold with a concentration of 50 mg/ml showed significantly elevated levels of β-galactosidase activity within explanted discs at 10 days compared to 10 mg/ml and 25 mg/ml fibrin. These findings inform efforts to optimise biodegradable scaffolds for the localised delivery of AAV in tissue engineering.
KayMLiuDHoogerbruggeP. Gene therapy. Proc Natl Acad Sci U S A1997; 94: 12744–12746.
2.
BonadioJSmileyEPatilP. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med1999; 5: 753–759.
3.
IsnerJWalshKSymesJ. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther1996; 7: 959–988.
4.
KayMGloriosoJNaldiniL. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med2001; 7: 33–40.
5.
PapanasNMaltezosE. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging2008; 3: 233–240.
6.
BainbridgeJWSmithAJBarkerSS. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med2008; 358: 2231–2239.
7.
KaplittMGFeiginATangC. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet2007; 369: 2097–2105.
8.
KayMMannoCRagniM. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet2000; 24: 257–261.
9.
ChioccaEAAguilarLKBellSD. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol2011; 29: 3611–3619.
10.
KwonISchafferDV. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res2008; 25: 489–499.
11.
MonahanPSamulskiR. AAV vectors: is clinical success on the horizon?Gene Ther2000; 7: 24–30.
12.
Penaud-BudlooMLe GuinerCNowrouziA. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol2008; 82: 7875–7885.
13.
KaeppelCBeattieSGFronzaR. A largely random AAV integration profile after LPLD gene therapy. Nat Med2013; 19: 889–891.
14.
XiaoXLiJSamulskiR. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol1996; 70: 8098–8108.
15.
SummerfordCSamulskiR. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med1999; 5: 587–588.
ConradCKAllenSSAfioneSA. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther1996; 3: 658–668.
18.
DuBWuPBoldt-HouleDM. Efficient transduction of human neurons with an adeno-associated virus vector. Gene Ther1996; 3: 254–261.
19.
KoeberlDDAlexanderIEHalbertCL. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A1997; 94: 1426–1431.
20.
ChampionHCGeorgakopoulosDHaldarS. Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation2003; 108: 2790–2797.
21.
ChandlerLDoukasJGonzalezA. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther2000; 2: 153–160.
22.
DoukasJChandlerLGonzalezA. Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther2001; 12: 783–798.
23.
BerryMGonzalezAClarkeW. Sustained effects of gene-activated matrices after CNS injury. Mol Cell Neurosci2001; 17: 706–716.
24.
BreenAStrappePKumarA. Optimization of a fibrin scaffold for sustained release of an adenoviral gene vector. J Biomed Mater Res A2006; 78: 702–708.
25.
SchekRMHollisterSJKrebsbachPH. Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. Mol Ther2004; 9: 130–138.
26.
BreenADockeryPO'BrienT. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. J Biomed Mater Res A2009; 89: 876–884.
27.
DaviesNGene-activated matrix. In: BowlinGWnekG (eds). Encyclopedia of biomaterials and biomedical engineering, New York: Marcel Dekker Inc., 2004, pp. 662–669.
28.
JoossKYangYFisherK. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol1998; 72: 4212–4223.
29.
LeeHHHaleemAMYaoV. Release of bioactive adeno-associated virus from fibrin scaffolds: effects of fibrin glue concentrations. Tissue Eng Part A2011; 17: 1969–1978.
30.
BezuidenhoutDDaviesNZillaP. Effect of well defined dodecahedral porosity on inflammation and angiogenesis. ASAIO J2002; 48: 465–471.
31.
MatsushitaTElligerSElligerC. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther1998; 5: 938–945.
32.
AuricchioAHildingerM, O CE. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther2001; 12: 71–76.
33.
RohrUWulfMStahnS. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods2002; 106: 81–88.
34.
MercerEHHoyleGWKapurRP. The dopamine beta-hydroxylase gene promoter directs expression of E coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron1991; 7: 703–716.
35.
GambleMWilsonIThe hemantoxylins and eosin. In: BankroftJDGambleM (eds). Theory and practice of histological techniques, London: Churchill Livingstone, 2002, pp. 125–139.
36.
WanLLiDWuQ. Perivenous application of fibrin glue as external support enhanced adventitial adenovirus transfection in rabbit model. J Surg Res2006; 135: 312–316.
37.
SakiyamaESHubbellJ. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release2000; 65: 389–402.
38.
ZischASchenkUSchenseJ. Covalently conjugated VEGF–fibrin matrices for endothelialization. J Control Release2001; 72: 101–113.
39.
McConnellKIGomezEJSuhJ. The identity of the cell adhesive protein substrate affects the efficiency of adeno-associated virus reverse transduction. Acta Biomater2012; 8: 4073–4079.
40.
LutolfMLauerFJSchmoekelH. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci U S A2003; 100: 5413–5418.
GaleanoMDeodatoBAltavillaD. Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia2003; 46: 546–555.
43.
NicklinSBueningHDishartK. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther2001; 4: 174–181.
44.
PajusolaKGruchalaMJochH. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol2002; 76: 11530–11540.
45.
HansenJQingKKwonH. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol2000; 74: 992–996.
46.
DenbyLNicklinSBakerA. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther2005; 12: 1534–1538.
47.
WhiteSNicklinSBuningH. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation2004; 109: 513–519.
48.
BuningHBraunFMHallekM. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs2004; 177: 139–150.
49.
JangJHKoerberJTKimJS. An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol Ther2011; 19: 667–675.
